The benefit of nonpharmacologic therapy to treat symptomatic osteoarthritis Yvonne C. LeeRobert H. Shmerling OriginalPaper 04 May 2008 Pages: 5 - 10
Abuse-deterrent opioid formulations: Are they a pipe dream? Nathaniel Katz OriginalPaper 04 May 2008 Pages: 11 - 18
Are there promising biologic therapies for osteoarthritis? David J. Hunter OriginalPaper 04 May 2008 Pages: 19 - 25
Lessons from animal models of osteoarthritis Wim B. van den Berg OriginalPaper 04 May 2008 Pages: 26 - 29
Extracellular matrix and pathogenic mechanisms in osteoarthritis Tim Hardingham OriginalPaper 04 May 2008 Pages: 30 - 36
Cell death in osteoarthritis Marcello Del Carlo JrRichard F. Loeser OriginalPaper 04 May 2008 Pages: 37 - 42
Licofelone: The answer to unmet needs in osteoarthritis therapy? Shrinivas K. KulkarniVijay Pal Singh OriginalPaper 04 May 2008 Pages: 43 - 48
The Post-NSAID Era: What to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis Carla R. ScanzelloNeal K. MoskowitzAllan Gibofsky OriginalPaper 04 May 2008 Pages: 49 - 56
Primary thrombosis prevention in aPL-positive patients Kathleen M. O’Neil Clinical Trials Report 04 May 2008 Pages: 59 - 61
Thrombolysis in antiphospholipid syndrome: Current hematologic perspectives René Y. McNall-Knapp OriginalPaper 04 May 2008 Pages: 62 - 66
Neurologic manifestations of the antiphospholipid syndrome: Integrating molecular and clinical lessons Eyal MuscalRobin L. Brey OriginalPaper 04 May 2008 Pages: 67 - 73
The enigmas of the lupus anticoagulant: Mechanisms, diagnosis, and management Richard A. MarlarSanam Husain OriginalPaper 04 May 2008 Pages: 74 - 80